Gastroparesis

Gastroparesis
Simple abdominal X-ray shows gastric distension with a large amount of material in the stomach, suggesting severe gastric hypomotility
Pronunciation	(/,ɡæstroʊ,pəˈriːsɪs/)
Specialty	Gastroenterology
Symptoms	Nausea, vomiting, abdominal pain, feeling full after consuming very little ("early satiety")
Complications	Malnutrition, fatigue, weight loss, vitamin deficiencies, intestinal obstruction due to bezoars, small intestinal bacterial overgrowth
Causes	Damage to the vagus nerve, chemotherapy-induced neuropathy, autonomic neuropathy
Risk factors	Diabetes, abdominal or esophageal surgery, infection, certain medications that slow the rate of stomach emptying, scleroderma, nervous system diseases, hypothyroidism
Diagnostic method	Barium swallow X-ray, barium beefsteak meal, radioisotope gastric-emptying scan (GES), wireless motility capsule (WMC), serial X-ray after ingesting radiopaque markers (ROM), gastric manometry, esophagogastroduodenoscopy (EGD), stable isotope breath test
Differential diagnosis	Peptic ulcer disease, gastric outlet obstruction, functional dyspepsia
Treatment	Dietary modifications, medications to stimulate gastric emptying, medications to reduce vomiting gastric electrical stimulation

Gastroparesis (gastro- from Ancient Greek γαστήρ – gaster, "stomach"; and -paresis, πάρεσις – "partial paralysis") is a medical disorder of ineffective neuromuscular contractions (peristalsis) of the stomach, resulting in food and liquid remaining in the stomach for a prolonged period of time. Stomach contents thus exit more slowly into the duodenum of the digestive tract, a medical sign called delayed gastric emptying. The opposite of this, where stomach contents exit quickly into the duodenum, is called dumping syndrome.

Symptoms include nausea, vomiting, abdominal pain, feeling full soon after beginning to eat (early satiety), abdominal bloating, and heartburn. Many or most cases are idiopathic. The most common known cause is autonomic neuropathy of the vagus nerve, which innervates the stomach. Uncontrolled diabetes mellitus is a frequent cause of this nerve damage, but trauma to the vagus nerve is also possible. Some cases may be considered post-infectious.

Diagnosis is via one or more of the following: barium swallow X-ray, barium beefsteak meal, radioisotope gastric-emptying scan, gastric manometry, esophagogastroduodenoscopy (EGD), and a stable isotope breath test. Complications include malnutrition, fatigue, weight loss, vitamin deficiencies, intestinal obstruction due to bezoars, and small intestinal bacterial overgrowth. There may also be poor glycemic control and irregular absorption of nutrients, particularly in the setting of diabetes.

Treatment includes dietary modification, medications to stimulate gastric emptying (including some prokinetic agents), medications to reduce vomiting (including some antiemetics), and surgical approaches. Additionally, gastric electrical stimulation (GES; approved on a humanitarian device exemption) can be used as treatment. Nutrition may be managed variously, ranging from oral dietary modification to jejunostomy feeding tube (if oral intake is inadequate). A gastroparesis diagnosis is associated with poor outcomes, and survival is generally lower among patients than in the general population.

Signs and symptoms

Gastroparesis has been linked to vomiting, bloating, early satiety, and epigastric pain. Symptoms of delayed gastric emptying tend to be exacerbated by eating, particularly after fatty foods and indigestible solids like salads and leafy vegetables. In general, nausea is the most commonly reported symptom, affecting up to 96% of gastroparesis patients. However, depending on the etiology, the predominant symptom reported can differ. The severity of gastric emptying dysfunction does not correspond to the severity of symptoms. Heartburn and poor glycemic control may be the only symptoms of delayed gastric emptying in diabetic patients. Physical examination in patients with gastroparesis may be completely normal or, in its more severe forms, dehydration and malnutrition, as well as a succussion splash, can be present.

Nausea in gastroparesis is usually postprandial, but morning or persistent nausea may occur. Vomiting is characterized by retching and forceful evacuation of gastric contents from the stomach up to and out of the mouth. Some patients may experience retching without gastric contents being expelled.

Postprandial fullness is an unpleasant feeling of stomach fullness that occurs after eating. Patients might characterize postprandial fullness as a feeling of food remaining in the stomach for an extended period of time. Satiation is a lack of hunger after eating. It is the inverse of hunger and appetite. Early satiety is the disappearance of appetite before nutrient absorption during food ingestion. Early satiation may be described by patients with gastroparesis as a loss of appetite or disappearance of appetite while eating. Early satiety is the sensation of stomach fullness that occurs shortly after beginning to eat and is out of proportion to the meal.

Bloating is a highly subjective feeling of increased abdominal pressure. Bloating without eating should be distinguished from postprandial fullness. It is sometimes, but not always, associated with food consumption.

Abdominal discomfort or pain is common, affecting 90% of gastroparesis patients. Idiopathic gastroparesis patients may experience more abdominal pain than diabetic gastroparesis patients. Physicians believe that postprandial epigastric pain is the most common symptom of gastroparesis. Abdominal pain has a wide range of symptoms. Around 40% of patients have localized epigastric pain, but it can be diffuse in some cases. Pain is usually classified as postprandial, but it can also occur at night and interfere with sleep. The severity of abdominal pain is unrelated to the impairment of gastric emptying.

Complications

Gastroparesis can lead to difficult glycemic control (which exacerbates gastric dysmotility), aspiration, bezoar formation, abnormalities in fluid and electrolyte balance, and inadequate nutrition intake resulting in weight loss.

Some patients may experience severe nausea and vomiting, which can lead to dehydration, as evidenced by orthostatic hypotension as well as acute renal insufficiency. Some patients with severe gastroparesis lose a significant amount of weight and suffer from nutritional deficiencies, necessitating small bowel feeding access to bypass the stomach.

Individuals with gastroparesis are also more likely to develop gastric bezoars. Bezoars are large masses of foreign substances and food that have become trapped in the GI tract, especially in the stomach. The incidence of bezoar formation in gastroparesis patients has been estimated to be approximately six percent based on a barium study.

There is a strong link between gastroparesis and the development of small intestinal bacterial overgrowth (SIBO). One study examined 50 gastroparesis patients using a glucose breath test and discovered that SIBO was present in 60% of their cohort. Furthermore, longer episodes of gastroparesis symptoms increase the risk of SIBO. Poor gastrointestinal motility (see enteric nervous system) and gastric acid production are believed to allow bacteria to colonize the small intestine. Furthermore, many individuals with gastroparesis are treated with acid-suppressive drugs, which significantly impair the GI tract's innate bactericidal activity. SIBO causes small bowel inflammation, impairing absorption and worsening nutritional deficiencies in gastroparesis.

Because of the debilitating symptoms, patients with gastroparesis are at risk of significant nutritional abnormalities. In one study, 305 patients with gastroparesis had their dietary intake and nutritional status evaluated, and the average caloric intake was 1168 kcal/day, which resulted in substantial nutritional deficiencies. Furthermore, 64% of gastroparesis patients consumed a calorie-deficient diet. Additionally, higher symptom scores were inversely proportional to caloric intake. Another study found that the severity of nutritional deficiencies was proportional to the duration of gastric emptying. Minerals like iron, fat-soluble vitamins, thiamine, and folate are commonly reported deficiencies. Iron deficiency is common in patients with gastroparesis.

Other complications include fluctuations in blood glucose due to unpredictable digestion times due to changes in rate and amount of food passing into the small bowel, a decrease in quality of life, since it can make keeping up with work and other responsibilities more difficult, and severe fatigue due to caloric deficit.

Causes

There are many possible etiologies of gastroparesis. Many cases are idiopathic. Others are secondary to chronic or systemic conditions. Gastroparesis may be also acquired after an infection or trauma, or it may be iatrogenic.

People with gastroparesis are disproportionately female. One possible explanation for this finding is that women have an inherently slower stomach emptying time than men. A hormonal link has been suggested, as gastroparesis symptoms tend to worsen the week before menstruation when progesterone levels are highest.

Idiopathic

Idiopathic gastroparesis (gastroparesis with no known cause) accounts for a third (or more) of all chronic cases. It is thought that many of these cases are due to an autoimmune response, perhaps triggered by an acute viral infection. Gastroenteritis, infectious mononucleosis, and other ailments have been anecdotally linked to the onset of the condition, but no systematic study has proven a link. In cases of post-infectious gastroparesis, patients have symptoms and go undiagnosed for an average of 3 weeks to 6 months before their illness is identified correctly and treatment begins.

Chronic conditions

It is frequently caused by autonomic neuropathy, occurring in about 30–50% of people with long-standing type 1 or type 2 diabetes. In fact, diabetes mellitus has been named as the most common known cause of gastroparesis, as high levels of blood glucose may effect chemical changes in the nerves. The vagus nerve becomes damaged by years of high blood glucose or insufficient transport of glucose into cells resulting in gastroparesis. Adrenal and thyroid gland problems could also be a cause.

Gastroparesis has also been associated with connective tissue diseases such as scleroderma and Ehlers–Danlos syndrome, and neurological conditions such as Parkinson's disease and multiple system atrophy. It may occur as part of a mitochondrial disease. Chronic gastroparesis can be caused by other types of damage to the vagus nerve, such as abdominal surgery.

Other causes

Transient gastroparesis may arise in acute illness of any kind, as a consequence of certain cancer treatments or other drugs which affect digestive action, or due to abnormal eating patterns. Heavy cigarette smoking is also a plausible cause since smoking causes damage to the stomach lining.

Patients with cancer may develop gastroparesis because of chemotherapy-induced peripheral neuropathy, immunosuppression followed by viral infections involving the GI tract, procedures such as celiac blocks, paraneoplastic neuropathy or myopathy, or after an allogeneic bone marrow transplant via graft-versus-host disease.

An analysis by University Hospitals Cleveland Medical Center of records from the TriNetX database found that the number of patients diagnosed with gastroparesis after being prescribed a GLP-1 receptor agonist (0.1% of the patients) was 250% greater than the number of patients diagnosed with gastroparesis who did not take a GLP-1 medication (0.04%).

Physiology and mechanism

The symptoms of gastroparesis are best understood in the context of the physiology of gastric emptying (GE). The stomach functions as a reservoir for food and nutritional content, which are broken down to produce chyme. Chyme is then released into the duodenum at a controlled rate to allow for maximum nutrient absorption. The controlled rate of chyme released is regulated by feedback mechanisms from the stomach and small intestines, which activate the vagus nerve and other hormones. The delay of any of the factors in gastric emptying causes disorganization or reduced frequency of antral contractions and thus delayed GE.

On the molecular level, it is thought that gastroparesis can be caused by the loss of neuronal nitric oxide expression since the cells in the GI tract secrete nitric oxide. This important signaling molecule has various responsibilities in the GI tract and in muscles throughout the body. When nitric oxide levels are low, the smooth muscle and other organs may not be able to function properly. Other important components of the stomach are the interstitial cells of Cajal (ICC) which act as a pacemaker since they transduce signals from motor neurons to produce an electrical rhythm in the smooth muscle cells. Lower nitric oxide levels also correlate with loss of ICC cells, which can ultimately lead to the loss of function in the smooth muscle in the stomach, as well as in other areas of the gastrointestinal tract.

Pathogenesis of symptoms in diabetic gastroparesis include:

• Loss of gastric neurons containing nitric oxide synthase (NOS) is responsible for defective accommodation reflex, which leads to early satiety and postprandial fullness.
• Impaired electromechanical activity in the myenteric plexus is responsible for delayed gastric emptying, resulting in nausea and vomiting.
• Sensory neuropathy in the gastric wall may be responsible for epigastric pain.
• Abnormal pacemaker activity (tachybradyarrhythmia) may generate a noxious signal transmitted to the CNS to evoke nausea and vomiting.

Diagnosis

Gastroparesis is suspected in patients who have abdominal pain, nausea, vomiting, or bloating, or when these symptoms occur after eating. Once an upper endoscopy has been performed to exclude peptic ulcer disease or gastric outlet obstruction as the root of their symptoms, those patients should be tested for gastroparesis.

Differential diagnosis

More than 30% of patients with severe gastroparesis symptoms also experience severe constipation. This may be linked to delayed small bowel and colon transit. If symptoms are refractory (especially in the setting of weight loss), or if an intestinal neuromyopathic disorder is suspected, then motility may be evaluated via antroduodenal manometry, wireless motility capsules, whole gut scintigraphy, or radiopaque markers. Extragastric dysmotility may also be treated with prokinetic medications.

Testing overview

There are several tests available to diagnose gastroparesis. Gastric emptying scintigraphy (GES) is the current gold standard. But it often cannot distinguish gastroparesis from functional dyspepsia, both of which feature bloating, and both of which may be part of a spectrum of gastric neuromuscular dysfunction. In addition, symptom severity may not correspond to the extent of delayed gastric emptying as measured by scintigraphy.

Alternatives include stable isotope breath tests with carbon-13, which is unreliable in the setting of many diseases; wireless motility capsules, which may permit a more thorough examination; and antroduodenal manometry, which is invasive but may provide some information as to the etiopathogenesis.

Other imaging modalities are rarely used. MRI is expensive. Ultrasound requires expertise and is challenging in the setting of obesity.

Gastric emptying scintigraphy

Griffith et al. first described GES in 1966, and it has since become the gold standard for diagnosing gastroparesis. Following an overnight fast, the patient consumes a standardized, radiotracer-bound, low-fat meal within 10 minutes of this test. A longer ingestion time may alter the results.

Most medical facilities use 99mTc sulfur colloid-labeled egg sandwiches or Egg Beaters egg whites with 1–2 slices of bread, strawberry jam, and water. Previously, studies labeled both the solid and liquid phases of a meal; however, present standard tests just label the solid phase of a meal, since liquid emptying only becomes delayed in the most advanced stages of gastroparesis. However, when assessing for postsurgical anatomic issues or ruling out dumping syndrome in postsurgical patients, testing liquid emptying is valuable.

Following ingestion, the patient undergoes standard imaging of the gastric area while standing, and the percentage of radioactivity left in the stomach is recorded using computerized software and normalized to the baseline value at 1, 2, and 4 hours postprandially. Gastric emptying is considered delayed if there is more than 60% retention at 2 hours and/or more than 10% retention at 4 hours.

Stable isotope breath tests with carbon-13

The stable isotope breath test involves using the stable isotope carbon-13 (13C) in a medium-chain fatty acid substrate such as octanoic acid. After that, the 13C-labeled substrate is attached to a food that can be digested, like muffins, or to Spirulina platensis, a blue-green algae that is 50–60% protein, 30% starch, and 10% lipids.

Following an overnight fast, pre-meal breath samples are taken, and then meals are consumed. 13C-octanoate is absorbed in the duodenum and liquefies to chyme after feeding and after the stomach has been emptied. It is then transported to the liver via the portal circulation and metabolized to 13-carbon dioxide (13CO2) before being exhaled during expiration.

Because stomach emptying is the testing process's rate-limiting step, the amount of 13CO2 present in an exhaled breath test represents gastric emptying. Every 30 minutes, post-meal breath samples are collected and analyzed using isotope-ratio mass spectrometry. For a total of 4–6 hours, samples are collected every 30 minutes.

The stable isotope breath test is unreliable for individuals with small bowel diseases like celiac disease, exocrine pancreatic insufficiency, liver disease, or lung disease because it involves duodenal absorption, 13C metabolism in the liver, and pulmonary exhalation of 13CO2. Physical activity is another factor that can influence CO2 excretion.

Wireless motility capsule

The US Food and Drug Administration has approved the wireless motility capsule (WMC) for the evaluation of gastric emptying as well as colonic transit time for individuals with suspected slow transit constipation. The capsule is 26.8 mm long and 11.7 mm wide, and it contains three sensors for temperature, pH, and pressure. Once ingested, the WMC continuously records measurements of the three variables as it moves through the gastrointestinal tract, and the information is wirelessly and in real-time transmitted to a receiver that the patient wears on their waist for the duration of the study.

Patients consume a standardized meal that includes a nutrient bar accompanied by 50 cc of water on the day of testing. Patients must fast for 6 hours following consuming a meal. For the duration of the study, they are asked to press the EVENT button, record specific events in a diary, and then the receiver is gathered and the data is downloaded for analysis.

Gastric emptying time is regarded as delayed if it is 5 hours or longer and is defined as the time required for the capsule to reach the duodenum, as determined by a pH increase of more than 3 units. Small bowel transit time is normally 2.5–6 hours and is calculated from the time the pH increases by more than three units to the time it drops by more than one unit and is sustained for at least 30 minutes. This drop denotes the capsule's passage to the cecum. The colon transit period (normal is 59 hours or less) is calculated from the time the WMC enters the cecum till it is expelled from the body, as indicated by a sudden drop in temperature or signal loss.

Recent studies have also shown that luminal pressure measurements can be used to differentiate diabetic gastroparesis, which is characterized by a reduced amount of contractions and motility indices when compared to healthy individuals. The ability to examine extragastric motility with a single test is another advantage of using WMC in the diagnosis of gastroparesis. This is useful because extragastric impaired motility occurs in more than 40% of those with suspected gastroparesis, and gastrointestinal symptoms do not correlate well with the gastrointestinal segment affected. Assessing the rest of the gastrointestinal tract in addition to gastric emptying provides information about motility in various segments of the gut, which can change management and improve symptoms.

Antroduodenal manometry

Antroduodenal manometry involves endoscopically or under radiographic fluoroscopy inserting a manometry catheter or transducer with pressure sensors into the pyloric channel in order to obtain information about gastric and duodenal contractions. Fasting and postprandial states are used to measure the pressure of the antral, pyloric, and duodenal contraction waves. The test can be performed in a stationary setting for 5–8 hours or in an ambulatory setting for 24 hours to evaluate duodenal motor function. Antroduodenal manometry reveals a decreased antral motility index in gastroparesis.

Antroduodenal manometry aids in differentiating between myopathic (scleroderma, amyloidosis) and neuropathic (diabetes mellitus) causes of impaired motility. The test shows a decreased frequency and amplitude of migrating motor complexes in patients with a myopathic condition. The migrating motor complexes in patients whose disease has a neuropathic etiology have a normal amplitude, but they are ill-coordinated and cannot propagate. This test is not widely available, and more validation research is required. It is an invasive test that necessitates expertise to perform and comprehend the results. Furthermore, it is technically challenging, and the catheter may move from the pylorus while an individual is fed and the stomach dilates.

Other imaging tests

Although transabdominal ultrasonography and magnetic resonance imaging (MRI) have been proposed as noninvasive diagnostic tools for gastroparesis, their use is currently restricted to research.

By measuring changes in the antral area, two-dimensional ultrasonography can provide information about gastric emptying, and complete gastric emptying is determined when the antral area goes back to its preprandial baseline. Three-dimensional ultrasound can provide information on meal distribution and stomach volume. It has also been proposed to use duplex sonography to examine transpyloric flow as well as liquid contents. While ultrasound appears to be an appealing safe technique, its use in the clinical setting is limited due to the significant expertise required and inadequate outcomes in obese patients.

Another appealing tool is MRI, which uses transaxial abdominal images to gauge gastric accommodation and emptying every 15 minutes. It can also distinguish between gastric meal and air and thus provide data on gastric emptying and secretions. It is, however, costly and necessitates specialized equipment; with the exception of research, it is not standardized across centers, limiting its use to research only.

Treatment

Treatment includes dietary modifications, medications to stimulate gastric emptying, medications to reduce vomiting, and surgical approaches.

Diet

Dietary treatment involves low-fiber/low-residue diets and, in some cases, restrictions on fat or solids. Eating smaller meals, spaced two to three hours apart has proved helpful. Avoiding foods like rice or beef that cause the individual problems such as pain in the abdomen or constipation will help avoid symptoms.

Pharmacotherapy

Dopamine antagonists

D₂ receptor antagonists are used to treat gastroparesis by reversing dopamine's inhibition of acetylcholine (ACh) release. This increases gastrointestinal contractility and resting tone, and improves motility in the stomach and proximal small bowel. Dopamine antagonist action in the central nervous system (CNS) also prevents nausea and vomiting.

Domperidone may be accessed by the US FDA's Expanded Access program. It is dosed 10–20 mg three times daily and at bedtime. But it is associated with an increased risk of cardiac dysrhythmias, hence its restricted availability. It is contraindicated in patients with corrected QT intervals of >470 ms in males or >450 ms in females.

Metoclopramide has more CNS adverse effects than domperidone and carries a US FDA boxed warning for tardive dyskinesia, a potentially irreversible condition. There are clinical guidelines specifically to mitigate this risk in its use, with doses limited to 5–10 mg orally before meals and at bedtime. A liquid formulation is recommended, and a new intranasal formulation is also available.

Other prokinetics

Among motilin agonists, erythromycin is well known to improve emptying of the stomach. Its prolonged use is limited by the development of tachyphylaxis; therapeutic effects may wane after a few weeks of consistent use. Clarithromycin and azithromycin, though less studied for this indication, share the same mechanism of action and (limited) utility. Azithromycin has the fewest drug interactions of the three.

Prucalopride, a 5-HT₄ receptor agonist, may also be tried, particularly if there is chronic constipation (for which it is labeled in Europe and US). Some evidence suggests it may improve symptoms and quality of life in gastroparesis.

Pyridostigmine, an acetylcholinesterase inhibitor, may facilitate emptying by increasing ACh in the gastrointestinal neuromusculature. It lacks rigorous clinical trials for this indication, but there is clinical experience with its off-label use as a prokinetic in several gastrointestinal motility disorders.

Other neuromodulators and antiemetics

The antidepressant mirtazapine has proven effective in the treatment of gastroparesis unresponsive to conventional treatment. This may be due to its antiemetic and appetite stimulant properties. Mirtazapine acts on the same serotonin receptor (5-HT3) as the popular antiemetic ondansetron.

A variety of other central neuromodulators, including (but not limited to) other antidepressants, may be tried for symptoms like bloating and distention (and not only in the setting of gastroparesis, but also for disorders of gut–brain interaction, or DGBI). They may reduce visceral pain or hypersensitivity, especially of a postprandial nature. They may also be selected to address any possible psychiatric comorbidities.

Other agents

Sildenafil, which increases blood flow to the genital area in men, is being used by some practitioners to stimulate the gastrointestinal tract in cases of diabetic gastroparesis.

Deprescribing

Gastroparesis presents with symptoms like those of slow gastric emptying caused by some opioid medications, some antidepressants, some allergy medications, some weight loss medications, and some antihypertensives. For gastroparesis patients, these medications may make the condition worse.

Drug development

Camicinal was an investigational motilin agonist that did not improve enteral feeding intolerance.

Other therapeutic interventions

In specific cases where treatment of chronic nausea and vomiting proves resistant to drugs, implantable gastric stimulation may be used. A medical device is implanted that applies neurostimulation to the muscles of the lower stomach to reduce the symptoms. This is only done in refractory cases that have failed all medical management (usually at least two years of treatment).

Medically refractory gastroparesis may also be treated with a pyloromyotomy, which widens the gastric outlet by cutting the circular pylorus muscle. This can be done laparoscopically or endoscopically (called G-POEM). Vertical sleeve gastrectomy, a procedure in which a part or all of the affected portion of the stomach is removed, has been shown to have some success in the treatment of gastroparesis in obese patients, even curing it in some instances. Further studies have been recommended due to the limited sample size of previous studies.

Prognosis

Long-term studies in gastroparesis patients show that it is not a benign disease and has significant morbidity and a poor prognosis due to the limited options for treatment. The mortality rate is highest in patients with decompensated gastroparesis who are more likely to develop complications. For example, one study discovered that over a 6-year period, 7% of those with gastroparesis died, with 22% requiring long-term enteral or parenteral feeding. 26% of these patients failed to respond to medical treatment, and 6% had gastric electrical stimulation. The 10 patients who died succumbed to metabolic issues, cardiac complications, renal failure, suicide, and bowel ischemia caused by adhesions.

Other research indicates that diabetic gastroparesis is associated with an increased risk of morbidity but not mortality. Olmsted County residents who had definite gastroparesis symptoms, as well as diagnostic testing for gastroparesis, had a 5-year estimated survival rate of 67%, which was significantly lower than the population average. Old age at the time of diagnosis has been linked to a lower chance of survival. Nondiabetic gastroparesis has been linked to a higher survival rate than diabetic gastroparesis.

Some evidence suggests that post-viral gastroparesis has a better prognosis and lasts less time than idiopathic gastroparesis. Cases of post-infectious gastroparesis are self-limiting, with recovery within 12 months of initial symptoms, although some cases last well over 2 years. In children, the duration tends to be shorter and the disease course milder than in adolescents and adults.

Prevalence

Post-infectious gastroparesis, which constitutes the majority of idiopathic gastroparesis cases, affects up to 4% of the US population. Women in their 20s and 30s seem to be susceptible. One study of 146 US gastroparesis patients found the mean age of patients was 34 years with 82% affected being women, while another study found the patients were young or middle aged and up to 90% were women.

There has only been one true epidemiological study of idiopathic gastroparesis which was completed by the Rochester Epidemiology Project. They looked at patients from 1996 to 2006 who were seeking medical attention instead of a random population sample and found that the prevalence of delayed gastric emptying was fourfold higher in women. It is difficult for medical professionals and researchers to collect enough data and provide accurate numbers since studying gastroparesis requires specialized laboratories and equipment.

See also

• Autoimmune gastrointestinal dysmotility
• Enteric nervous system
• Intestinal pseudo-obstruction, or enteric neuropathy

Further reading

• Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L (January 2013). "Clinical guideline: management of gastroparesis". The American Journal of Gastroenterology. 108 (1): 18–37, quiz 38. doi:10.1038/ajg.2012.373. PMC 3722580. PMID 23147521.
• Parkman HP, Fass R, Foxx-Orenstein AE (June 2010). "Treatment of patients with diabetic gastroparesis". Gastroenterology & Hepatology. 6 (6): 1–16. PMC 2920593. PMID 20733935.
• Kim BJ, Kuo B (January 30, 2019). "Gastroparesis and Functional Dyspepsia: A Blurring Distinction of Pathophysiology and Treatment". Journal of Neurogastroenterology and Motility. 25 (1). The Korean Society of Neurogastroenterology and Motility: 27–35. doi:10.5056/jnm18162. ISSN 2093-0879. PMC 6326193. PMID 30509017.

External links

• Overview from NIDDK National Institute of Diabetes, Digestive, and Kidney Diseases at NIH
• [2] Gastrostars - Patients organization for everyone with a stomach paralysis and other additional physical conditions such as a paralyzed or slow working intestines.